FAD Encapsulation in Gold Nanoparticles for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are often aggressive and toxic, affecting both cancerous and healthy cells, leading to undesirable side effects, and there is a need for a targeted and non-toxic approach to effectively prevent and treat cancer.
Innovation Solution
Flavin Adenine Dinucleotide (FAD) is used alone or in combination with a vector, such as gold nanoparticles or biopolymers, to target and treat cancer cells, interfering with gene expression and cellular differentiation mechanisms, while being non-toxic to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional aggressive anti-cancer treatments are used, then cancer cell destruction is improved, but toxicity to healthy cells increases
Solution Approach 1:
The patent applies local quality by making FAD selectively accumulate in cancer cells through their abnormal metabolic characteristics (Warburg effect), while maintaining non-toxicity to healthy cells. The compound is administered systemically but achieves localized action at the cancer site through differential cellular uptake and retention mechanisms.
Solution Approach 2:
The patent uses FAD as an intermediary substance that exploits the metabolic differences between cancer and healthy cells. By targeting the altered metabolic pathways in cancer cells (particularly glucose metabolism and redox balance), FAD acts as a selective mediator that destroys cancer cells while sparing healthy tissue.
2Productivity
If FAD is administered systemically, then cancer cells are reached throughout the body, but bioavailability and stability decrease
Solution Approach 1:
The patent employs parameter changes by modifying FAD's physicochemical properties through conjugation with hydrophobic moieties (fatty acids, cholesterol, or vitamin D derivatives). These modifications alter solubility, membrane permeability, and metabolic stability parameters, enabling systemic administration while maintaining sufficient bioavailability and circulating half-life.
Data Source
AI summary
The invention concerns Flavine adenine dinucleotide (FAD) for use in preventing and/or treating cancer. The FAD is favorably encapsulated at least partially in a particle with a vector to improve its absorption and distribution while limiting its destruction, in particular by blood hydrolases. The invention relates to the pharmaceutical field and more specifically to oncology or cancerology.